


The International Glaucoma Association Ltd
Report and Financial Statements
31 July 2019



WEDNESDAY



A8KL6B56

A25

18/12/2019

#366

COMPANIES HOUSE

IGA Annual Report and Financial Statement 2018/2019

Contents

	Page
Our Objectives and Activities	2
Strategic report 2018/19 – achievements and performance	4
Campaigning & awareness	4
Advice & Support	6
Glaucoma research	8
Financial Review	9
Supporting the IGA – the year in fundraising	11
Investment Policy	13
Reserves Policy	13
Remuneration Policy	13
Future plans – 2020 and beyond	14
IGA Trustees, Advisors, and senior staff	15
Structure, Governance and Management	16
Related Parties and Connected Charities	16
Risk management	16
Statement of Trustee Responsibilities	17
Independent Auditors Report	19
Financial Statements	21


Our objectives and activities for the year ending 31 July 2019


Glaucoma is a blinding eye disease affecting around 700,000 people in the UKⁱ. If detected early and treated appropriately, most people with glaucoma will retain useful sight for life. But it is estimated that half those living with glaucoma don't know they have it, and these people risk serious sight loss or blindness as a result. Glaucoma is sometimes called 'the silent thief of sight' because the most common types of the disease are asymptomatic, and sight is lost so gradually that people often don't realise they have it.

Glaucoma is usually detected through a routine eye test at a community opticians', but uptake is patchy. The International Glaucoma Association (IGA) campaigns to raise awareness of glaucoma and encourage good eye health so that fewer people lose sight needlessly.

Once diagnosed, people with glaucoma need access to appropriate medical and surgical options and need to adhere to treatment – usually for life. However, this treatment can be complex and confusing, and research has shown that 40% - 80% of the information provided by healthcare professionals is forgotten immediately by patients, and that almost half is recalled incorrectly.ⁱⁱ The people we support often report an information gap: many don't fully understand their condition, which makes treatment choice and adherence challenging, and can cause great anxiety and impact negatively on daily life. The IGA aims to plug this information gap by providing advice and support that helps people to live well with glaucoma.


The chance of having glaucoma increases with age, and as our population ages, the number of people affected is growing. By 2025 about 850,000 in the UK will be living with glaucoma and it is predicted that there will be around 2.6 million glaucoma suspects: people who show signs indicative of the disease.





Hospital eye clinics are already stretched beyond capacity, and many clinicians are struggling to provide the level of care and support they would wish to. The tools available to them for diagnosis, care and treatment are developing fast, but depend on vital research funding to test new medical and surgical models and new ways of working. The IGA is committed to funding high quality glaucoma research that will have a real impact on the lives of those affected.

Our constitution lists our charitable objectives as the preservation of sight through education and the advancement of glaucoma research, and this is how we worked to achieve these aims during 2018/19:



Our campaigning and research goals are ambitious and require change at scale throughout the UK – as such, they are essentially longer-term goals. The growing prevalence of glaucoma means that our advice and support work will also be needed in the long-term, but the benefits for the people we support are immediate and transformative.

The IGA is a membership charity with around 4,000 members, including people living with glaucoma and the professionals who support them. Membership is not required to access services, and our support is freely available to anyone who needs it.

Strategic report 2018/19 – achievements and performance

1. Campaigning & awareness to prevent needless sight loss


Our campaigning and awareness work last year targeted 3 groups:

The general public: people unaware of glaucoma and who might be at risk, or even unknowingly living with disease. Some ethnic groups are at increased risk of certain types of glaucoma, and older people and those with close family members who have glaucoma are also at high risk. Men are 16% more likely than women to have serious sight loss at the point of diagnosis.

What we did:

- Ran a multimedia eye health awareness campaign during World Glaucoma Week in March 2019 and worked with pharmaceutical company Santen to produce a social media quiz simulating glaucoma sight loss.
- For Glaucoma Awareness Week in June we worked with partners Specsavers on a successful UK-wide eye health check press campaign, and we mailed awareness packs to over 1,100 hospital eye clinics and optometrist practices, encouraging clinicians to have conversations with patients about eye drops. A radio day using artificial intelligence in eye health as a public awareness 'hook' reached approximately 7.8m listeners.
- Ran a multimedia campaign during Ramadan in May 2019 that aimed to prevent Muslim glaucoma patients stopping eye drop use in the belief that it would break the fast. We were grateful to the Muslim Council for Britain and a number of Muslim medical professional associations for their help in getting the message out to several hundred mosques and many community organisations.

Nearly 50% of people filling a glaucoma eye drop prescription for the first time had stopped using it within 6 months.





Common side effects of eye drops:

- **Sore, red and painful eyes**
- **Skin discolouration**
- **Lash growth that requires trimming**

Healthcare professionals - With our resources spread thinly across the UK and with increasing numbers facing this sight-threatening condition, one route to increased impact is to work with other agencies. We want professionals to signpost people to our services, distribute our publications and messages,

What we did:

- Developed and delivered a new training course on eye drop adherence for Eye Clinic Liaison Officers (ECLOs), in partnership with the RNIB. The eye health sector aims to have an ECLO in every UK eye clinic, and our aim was to for ECLOs to gain the skills and knowledge of eye drops to enable them to provide dedicated adherence support to glaucoma patients. So far the course has been delivered to 8 groups across the four nations. ECLOs reported a 65% increase in confidence and knowledge of glaucoma, a 97% increase in knowledge of eye drops, and a 154% increase in knowledge of the aids available to help patients use eye drops.
- Attended and exhibited at a range of national ophthalmic, optometric and sight sector conferences in order to increase access to and uptake of our services.
- Provided organisational support to the UK and Eire Glaucoma Society (UKEGS) and the UK Paediatric Glaucoma Society (UKPGS). In December 2018 we organised an extremely successful annual UKEGS conference at City University, London, cementing good relations between the charity and leading ophthalmologists from across the UK and beyond. The IGA holds funds for these two bodies, acting as agents for them, as outlined in note 19.
- Facilitated patient recruitment into research studies for 9 academic institutions and supported 8 major applications for research funding.

Policy makers, planners and commissioners – we want the patient perspective to be heard when decisions are made about the design and delivery of glaucoma care.

What we did:

- Increased our level of contact with beneficiaries and shared their views and needs more comprehensively within the charity and used to influence future services. This was helped by the recruitment of a new post of Head of Patient Support Services. In autumn


IGA Annual Report and Financial Statement 2018/2019

2018 two patient conferences were held in Manchester and Newcastle, and were so well received that two more were held in Leicester and Bristol in 2019. In 2020 we aim to deliver more regional events, and in particular to ensure that we engage and get feedback from not just IGA members, but from a wider pool of people affected by glaucoma.

- Worked with the UK Ophthalmology Alliance on the development of new Patient Standards; continued to work with the DVLA to improve liaison with glaucoma patients; submitted views on changes to national tariffs and responded to Moorfields consultation on moving premises; supported the work of the Clinical Council on Eye Health Commissioning; worked with NHS Scotland Education to facilitate patient input into the development of a new training course for Scottish optometrists; supported the pharmaceutical company Santen's project on improving eye drop adherence; and facilitated IGA members' responses to a number of other national consultations.

2. Advice & support to help people live well with glaucoma

Sightline is our telephone helpline, providing advice, information and support to people with glaucoma every weekday. It is staffed by two full-time Advisors, and operates from Monday to Friday. The most common calls related to surgery or laser treatment and eye drops.



New methods of analysing call topics were introduced during the year which are providing additional insights into patients' needs. It is fairly common for numerous topics to be discussed during one call, but historically only the primary call reason was logged. More detailed recording and analysis recently revealed the need for a new publication on cataracts and glaucoma and this is being commissioned. A full thematic analysis will be published in the journal Eye in January 2020.

IGA Annual Report and Financial Statement 2018/2019

Our range of free **information booklets** are authored and edited by leaders in the fields of ophthalmology and optometry and all are reviewed by a patient panel before publication. We print and despatch tens of thousands of leaflets every year, mainly to hospital eye clinics, at a cost of just over £20,000. Measuring their impact is challenging, but we have again received significant anecdotal feedback about their value, and monitoring showed that 24% of first-time Sightline callers heard about the IGA via our publications and posters.

All our publications – and additional information – are available on our **website**. The site also hosts an online patient forum, although sadly the forum's usefulness has been compromised by increasing levels of spam which have proved hard to control. In 2018 we put a 3-year ICT strategy into practice to underpin the development of support services, and we are pleased to report that we completed Phase I (new server, improved security and new software platforms) on time and under budget. Phase II will deliver a new website in Summer 2020, with improved functionality. Staying with technology, in 2018 we started to scope our beneficiaries' level of digital engagement and their appetite for services provided using live webchat, webinars, chatbots etc. We ran an online survey and held focus groups at regional patient conferences, which provided valuable information to inform the next stages of service planning.

Our members receive patient information and news of the latest treatment and research developments via our **quarterly magazine 'IGA News'**. Members also receive invitations to regional events and to participate in clinical research programmes.

Our **Buddy service** matches people facing surgical procedures with volunteer Buddies who have experienced the procedures themselves. Buddies provide reassurance and emotional support, and improve patients' ability to play an active and informed role in the management of the condition. We matched 42 partnerships last year, and given the impact we are keen to expand provision in the coming year.

'Just wanted to say a HUGE thank you for arranging the 'Buddy' call for George. He said "I don't know what I'm going to say" and nearly hour and a quarter later he and Alison said goodbye to each other! ...the previous day he'd had a major wobble and more or less decided he wasn't going to go ahead [with treatment] seeing his sight had deteriorated so much He needed to get his head back into a good place, and Alison did just that. It's knowing someone who 'sees' exactly as you do and understands what you are going through that makes such a difference.'

Marilyn

Because health service policy and delivery differ across the regions and countries of the UK, our patient support work is reinforced by four **regional Development Managers** covering Scotland, London and the South East, Wales and the West Country and the North East of England. Their role is to influence regional commissioning practice and service delivery, establish patient support groups, raise awareness of glaucoma, and work with healthcare professionals to improve provision and ensure the patient voice is heard. Regional staff are supported by a small number of local volunteers who help disseminate

IGA Annual Report and Financial Statement 2018/2019

IGA information, give presentations to raise awareness and run events. We are enormously grateful to them for giving so generously of their time, skills, and enthusiasm.

3. Glaucoma research

The IGA supports research in two ways: by funding an annual grants programme, and by funding the IGA Professor of Glaucoma and Allied Studies at University College London (UCL).

The grants programme funds research into the nature, causes, detection, treatment and prevalence of glaucoma. Grant making is overseen by a grants panel – a sub-committee of the board of trustees - chaired by Nick Strouthidis MBBS MD PhD FRCS FRCOphth FRANZCO, and supported by clinical colleagues, patients and lay representatives. A strict conflict of interest consideration is applied, and individual panel members step down if a conflict exists.

In 2018/19 six grants were agreed:

- £99,960 was awarded to Dr Victor Hu from the London School of Hygiene and Tropical Medicine for a two-centre study (UK and Tanzania) 'Detecting glaucoma using low-cost portable and easy to use tests'
- £30,000 was awarded to Professor Heather Waterman from Cardiff University for a nursing study 'The electronic monitoring device EASY label'
- £24,995 was granted to Dr Tamsin Callaghan of City University of London for a study of the feasibility of visual fields monitoring.

Two grants were made in partnership with the UK & Eire Glaucoma Society:

- £30,300 to Professor Colin Willoughby of Ulster University for the study 'Preventing fibrosis in the trabecular meshwork to improve surgical treatment'
- £30,000 to Professor Colm O'Brien from Misericordiae University Hospital Dublin for 'The role of target molecules in optic nerve damage'.

The final award was a small grant joint-funded by the IGA and the charity Fight for Sight

- £15,000 to Dr Neeru Vallabh of the University of Liverpool for a study entitled 'Metagenomics of the ocular surface microbiome: the effects of preservatives in topical glaucoma and dry eye treatment'.

Once a grant has been awarded, funding is paid against a schedule agreed at the beginning of the study, and it is not uncommon for grant payments to be spread across several financial years. Regular reports are provided by the researcher, and the final payment is made on approval of a final report.

Given the recent high levels of legacy income, in June 2019 trustees agreed their highest ever annual research budget, committing £450,000 for the year 2019/20. Next years' programme includes two new grants of £100,000: one to fund a PhD in glaucoma research, the other to commission research into digital glaucoma support services that could potentially form the basis of future IGA support.

IGA Annual Report and Financial Statement 2018/2019

A key aim for 2018/19 was to develop a new Clinical Advisory Panel (CAP) to replace the previous Medical and Scientific Advisory Committee, and this was achieved by the end of the year. The CAP comprises 23 individuals, including acknowledged experts in the field of glaucoma, IGA trustees and patient representatives. They will act as a pool for research award panels and will take on the role of advising on clinical strategy and horizon scanning so the charity understands in advance the main influences affecting glaucoma care. This should enable us to deliver clearer timely messages on clinical issues, and use these to influence our strategy for service and information delivery.

Our commitment to glaucoma research is also delivered through our support for **the IGA Chair of Ophthalmology for Glaucoma and Allied Studies at UCL** currently Professor David (Ted) Garway-Heath. Through the Chair, the charity both increases its profile and advances the wider cause of research and learning in the field of glaucoma. The Trustees are delighted with another extremely successful year, during which Professor Garway-Heath was again voted onto 'The Ophthalmologist' global power list of the top 100 most influential people in ophthalmology.

During the year Professor Garway-Heath was Chief investigator in three current trials and Co-investigator in a number of multi-million pound studies including 'Imaging-based CUSTOMised EYE diagnostics; Horizon 2020', 'Treatment of Advanced Glaucoma Study' (TAGS trial), and 'Health-Related Quality of Life in two treatment pathways for primary open angle glaucoma and ocular hypertension'.

The Professor lectured at the Association for Research in Vision and Ophthalmology annual meeting, the worlds' most important scientific congress in vision research; this was just one of 25 national and international lectures he was invited to give last year, at each of which the IGA was acknowledged. Professor Garway-Heath continued his Presidency of the European Glaucoma Society last year, organising and overseeing the 13th biennial Congress in Italy, which attracted nearly 2,800 participants from 87 countries.

Back in the UK, the Professor was Lead for the Whole Building Design Workstream at Moorfields and the Institute of Ophthalmology at UCL, producing a creative strategy brief for the new joint Moorfields and Institute building. The Professor also continues to be active in teaching and he supervises a number of postgraduate students.

A full report on the Professor's activities for the year is available on request.

Financial review

The charity ended 2018/19 in very sound financial shape. Overall income increased by c. £25,000 to £1,870,935 thanks to another extremely strong legacy year. Legacy income of £1,435,418 comprised 76.7% of total income (2018/19: 78.6 %), and the Trustees are


IGA Annual Report and Financial Statement 2018/2019

extremely grateful to all those people who remembered the charity in their wills. Without their generosity most of our work would simply not be possible.

Other voluntary income increased by £28,420 to £287,702 (note 2). Full details are provided in the fundraising section on page 10, but it is worth noting here that we were particularly pleased that we have almost succeeded in halting the long-term decline in membership subscriptions, which fell by less than 1% last year. Hopefully this is a sign that we can buck the downward trend in membership affecting so many UK charities.

Investments performed relatively well during the year, and income rose by £21,570 to £112,572. Other income was stable at £35,243 (2017/18: £43,519). Within this, grants received totalled £24,112 comprising £10,000 from UKEGS towards a research award of £60,000 (the remainder funded by the IGA), support from the NIHR Moorfields Biomedical Research Centre towards the IGA Professor's costs, and a small grant from UKPGS towards the costs of the administrative and financial management support provided by the IGA.

Overall expenditure increased by £103,393 to £1.162m. As the cost of generating funds was stable at £134,647 (2017/18: £135,852), the increased spending was all on charitable activities:



2018/19

Research spending was back to its expected level at £320,722, following an unusually low prior year when many trials experienced delays and fewer grant payments were claimed.

Patient information and advice services was again the highest spending activity area at £601,212. This was a 26% increase on the previous year, due partly to a minor restructure

IGA Annual Report and Financial Statement 2018/2019

and the recruitment of a Head of Patient Support Services which focused our activity in this area.

The charity spent £73,355 on work with professionals, and £33,018 on campaigning and advocacy work. Both areas of expenditure were down on previous year, the former due in part to a slight decrease in attendance at paid-for healthcare exhibitions pending a review of their effectiveness, and the latter due in part to the irregular (intermittent) nature of external consultations. The role of Communications Manager was also vacant while the restructure bedded in. As this role historically carried out much of our campaigning and work with professionals, spending levels were lower than in the previous year.

Restricted funds totalled £1,574,474. The largest of these is the Chair Fund which holds funds for research and to meet the cost of the IGA Professor of Ophthalmology for the remaining 7 years of his 8-year term, and the North East Fund which is being used to fund the post of North East Development Manager. During the year restricted research income of £51,371 was received from the Christmas appeal and from gifts kindly left to the IGA in wills. This was spent in full during the year. A further gift of £20,000 from an anonymous charitable trust was restricted for use in the London area, and was spent in full on awareness raising activities with BAME communities.


Supporting the IGA – the year in fundraising

Our supporters are amazing, and we are so grateful for everything they do. It is only with their support, donations and personal recommendation to others that the IGA is here for anyone who needs us. Thank you to everyone who has contributed; your support is greatly valued.

During the year our Fundraising Manager again committed time to development work on our supporter and member database, which impacted to some extent on the time available for direct fundraising activity, but which will in time improve our ability to communicate effectively with our different supporter bases. She also dedicated time to legacy work, notably to renewing legacy advertising and running a new Free Will Writing campaign. We hope this will be well received by our supporters, but appreciate that this is a long-term piece of work, and unlikely to produce short-term results.

As reported in the Financial section, voluntary income for 2018/19 rose by £28,420 compared to the previous year.

IGA Annual Report and Financial Statement 2018/2019



In common with many other charities, we expected individual giving to be adversely affected post-GDPR by a reduction in the number of supporters we were able to engage with. However, we were delighted that the two supporter appeals of 2018/19 generated £34,757 - an increase of £19,004 - due mainly to a very successful Christmas appeal in support of research. We are extremely grateful to those supporters who have consented to be contacted by the charity for fundraising purposes: without their agreement and generosity, this avenue of fundraising would be closed to us.

Individual donations were £56,468, slightly lower than the previous year but still a wonderful sum. Gifts made In Memory of a loved one fell by over half to £9,753.

Income from charitable trusts and foundations was its highest for many years, at £80,311, and we would like to thank them for their generous support:

The Dandy Charitable Trust	The Wyseliot Rose Charitable Trust
The Emily Weircroft Charitable Trust	The Wyndham Charitable Trust
The Broadoak Trust	The Ronald Miller Foundation
The Henry Nelken Charitable Trust	The Edith Murphy Foundation
The William Howarth Trust	Blindcare
and an anonymous Trust that kindly funded our work in London	

Blindcare is a historical fundraising collaboration between several sight sector charities; it produced income of c. £29,000 during its final year and has now completed a planned transfer to another charity.

Community and individual fundraising activities was stable at £29,004 (£30,227 2018/19). Huge thanks go to all those fundraisers across the UK who ran, cycled, climbed and baked

IGA Annual Report and Financial Statement 2018/2019

for us in the past year. Particular thanks again go to our past Chair, ophthalmologist Keith Barton for another heroic London to Paris bike ride in aid of the IGA.

Corporate support rose to £20,450 and we are grateful to partners including Specsavers and pharmaceutical companies Santen and Thea for their financial support, but just as importantly, for helping us extend our reach and promote our work to a wider audience.

The trustees are pleased to report that once again no complaints were received about our fundraising activities during the year. We would like to extend our very grateful thanks to the kind individuals who have supported the charity during the past year, by contributing financially and by donating their time and skills. We are extremely grateful for their support.

Investment policy

Rathbone Investment Management Ltd manages the charity's assets on a discretionary basis. The trustees have instructed that the assets can be invested widely and should be diversified by asset class, manager and security, adopting a medium risk profile and avoiding direct investment in companies predominantly involved in the production of tobacco, which is proven to have an adverse effect on eye health.

The investment managers' performance is reviewed regularly against annually agreed benchmarks. Given the ongoing uncertainty generated by Brexit the Trustees decided against a move to Rathbone's pooled charity fund but will review this decision periodically in the year ahead.

Reserves policy

The trustees consider it prudent to hold free reserves to allow for periods of reduced income, cope with sudden short-term increases in expenditure, and to provide cover for risks, contingencies and unforeseen events.

The required level of reserves is reviewed each year, and summarised in a Reserves Policy. For 2019/20 the required level of unrestricted reserves was set at £3,740,000, comprising 12 months' operating costs and lease commitments, plus funds designated for equipment replacement, project and infrastructure development, and research investment. In 2019 £300,000 was added to the designated Research Investment Fund which now totals £1.6m, in pursuance of our aim to build a larger fund that will generate sufficient income to ensure we can fund future research priorities.

Actual reserves held at 31 July 2019 were £4,684,293, which is higher than minimum requirements due to unusually high levels of legacy income in the past three years. However, over the longer-term this income stream has been highly volatile, and given that the charity predicts an operational deficit for 2019/20, the trustees feel the current level of reserves is reasonable.

Remuneration policy

When setting salaries, trustees are guided by a Remuneration Policy that considers factors such as pay comparability (benchmarked within our own sector but also referencing public

IGA Annual Report and Financial Statement 2018/2019

and private sector pay increase estimates), affordability, sustainability, and appropriateness. The IGA aims to set salaries at a level where the ratio between the highest and lowest full-time equivalent is below 4.5:1 and the ratio between the highest and median (midpoint) salary is less than 3.5:1. As at 1 August 2019 these ratios were 3.2:1 and 2.2:1 respectively.

Future plans – 2020 and beyond

Our main challenge in the years ahead will clearly be to meet the needs of the rising numbers of people affected by glaucoma.

One way we will achieve this is to work with and through partner organisations, and we intend to do this partly through training delivery. We aim to roll out the successful 2019 ECLO training course to other eye health professionals, beginning in autumn 2019 with rehabilitation workers, followed by a new accredited course for optometrists in 2020. This will be followed by an accredited course for pharmacists, building on the 2018 research project involving pharmacists which found that interventions by pharmacists can significantly increase patient understanding and confidence in managing their treatment.

We aim to tailor our communications with colleagues by professional background to achieve more focused outcomes for patients. We will review and refine professional membership categories in 2020 and move to digital communications to lessen environmental impact and increase cost-effectiveness. The UKEGS AGM in November 2019 will propose a merger into the IGA. If agreed, this will strengthen our links with the ophthalmological community and provide a secure future for UKEGS' knowledge exchange and research network.

Given our unpredictable income levels, we face the prospect of having to do more with less, so need to ensure we work smartly and cost-effectively. The development of digital support services will be key to this, and in 2020 we hope to commission research into how we can use technology to effectively meet patients' future information and support needs.

We can work more smartly by focussing resources on those most at risk of glaucoma sight loss, including BAME communities and hard-to-reach groups in socioeconomically deprived areas with reduced access to healthcare. Increasing brand awareness and marketing is needed to achieve this, together with targeted campaign activity. A minor brand refresh is planned for 2020, plus a new website, much broader use of social media and production of a film for Ramadan 2020. With the recruitment of a new Communications and Engagement Manager in autumn 2019, we have significantly increased our digital skill base, and are confident of being able to make real progress in this area, and to increase data driven decision-making in the year ahead.

IGA trustees, advisors and senior staff

Trustees

The Trustees (who are also Directors under company law) are:

Prof. Philip Bloom	Chair
David Sanders	Hon Treasurer
Stephen Epstein	Vice Chair
Dr Susan Blakeney	Julian Exeter
Prof. Anthony King	Yolanda Laybourne
Ray Spendiff	Nicholas Strouthidis
Mary Shaw (to 15.3.19)	Sheila Page (to 15.3.19)
Christine Wall (from 15.3.19)	Dr Roxanne Crosby-Nwaobi (from 15.3.19)

Chief Executive and Company Secretary

Karen Osborn

Company Number

1293286

Charity Number

274681

OSCR Number

SC041550

Registered office and operational address

Woodcote House
15 Highpoint Business Village
Henwood
Ashford
Kent TN24 8DH
www.glaucoma-association.com

Bankers

Barclays Bank plc 1 Churchill Place London E14 5HP	CAF Bank Limited 25 Kings Hill Avenue Kings Hill Kent ME19 4JQ
HSBC Bank plc Camberwell Green 23 Denmark Hill London SE5 8RP	

Auditors

Calcutt Matthews
Chartered Accountants
19 North Street
Ashford
Kent TN24 8LF

Investment Managers

Rathbone Investment Management Ltd
8 Finsbury Circus
London EC2M 7AZ

Structure, governance and management

The IGA is a charitable company limited by guarantee incorporated on 15 July 1976 and registered as a charity on 20 December 1977. As the IGA is both a charity and a company limited by guarantee, all Board members are Directors for the purposes of company law and Trustees for the purposes of charity law. The objects of the charity are defined by its Articles of Association (last updated in 2015), which also set out trustees' powers and the permitted activities of the charity.

When reviewing our objectives and planning future activities, the Trustees refer to Charity Commission guidance on public benefit; all the IGA's activities are undertaken to further our charitable purposes for public benefit.

The Board comprises up to 15 trustees. The majority are elected by IGA members but up to three may be co-opted by the Board. A Trustee Handbook sets out trustee roles and responsibilities, an induction process is in place and ongoing training is offered.

Trustees retire after serving a three-year term, but are eligible for re-election to a maximum of twelve years' service. The Board conducts occasional audits to identify gaps in skills or knowledge, and a formal performance review is planned for 2020. The current Board comprises people living with glaucoma, and others with backgrounds in ophthalmology, nursing, optometry, finance and business.

During the year the Board had two sub-committees: a Finance and Governance Committee that oversees finance, investments, risk management and policy, and a Grants Committee that oversaw research awards.

Day to day responsibility for service delivery and for ensuring that charitable, strategic and financial aims are met is delegated to a Chief Executive, supported by a small Senior Management Team. At year-end the charity had a staff team of 17 (13.4 fte).

Related parties and connected charities

There were no related parties or connected charities during 2018/19, but the IGA acted as an agent for the United Kingdom and Eire Glaucoma Society (UKEGS) and the United Kingdom Paediatric Glaucoma Society (UKPGS). The IGA provides infrastructure support to both groups; this gives us access to leading ophthalmological professionals, whose help we call on for patient events and patient information publications.

Risk management

Risks are reviewed at least annually, or whenever there is material change. A Risk Register measures the likelihood of an occurrence and the potential severity of impact, and details the controls that are in place to manage them. Risks are monitored and communicated regularly to the Board, and risk management forms an integral part of strategic planning.

The two key risks of 2018/19 were:

- Data security risk.

IGA Annual Report and Financial Statement 2018/2019

We again made improvements to our systems and ICT infrastructure during the year, but this took place against a backdrop of increased regulation and increasing cyber security risk. We continue to regularly review our procedures and train our staff, and Cyber Essentials accreditation is planned for 2019/20.

- Low income levels, in an environment of highly unpredictable legacy income. Fundraising strategy and performance were reviewed in autumn 2019 and a new strategy will be developed following agreement of a new strategic plan in early 2020. In the meantime, risk is managed by cash flow monitoring and holding adequate reserves to cover any medium-term shortfall.

Statement of Trustee responsibilities

The Trustees are responsible for preparing the Trustees' report including the strategic report and financial statements in accordance with applicable law and United Kingdom accounting standards (UK generally accepted accounting practice).

Company law requires the Trustees to prepare financial statements which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time, the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the Trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and

IGA Annual Report and Financial Statement 2018/2019

- the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees' Report is approved by order of the Board of Trustees, and the Strategic Report (included therein) is approved by the Board of Trustees in their capacity as Directors, in their meeting on 26 November 2019, and signed on its behalf by

A handwritten signature in black ink, appearing to read 'P. Bloom', with a stylized flourish at the end.

Professor Philip Bloom
Chair

IGA Annual Report and Financial Statement 2018/2019

Report of the Independent Auditors to the Trustees of the International Glaucoma Association

We have audited the financial statements of International Glaucoma Association for the year ended 31 July 2018 on pages 21 to 35. The financial reporting framework that has been applied in their preparation is applicable law and FRS 102 (effective January 2015), as well as the Statement of Recommended Practice for Charities (effective January 2015).

This report is made solely to the IGA's members and Council of Management, as a body, in accordance with Section 144 of the Charities Act 2011, and regulations made under Section 154 of that Act, as well as Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the group's and parent charitable company's members and Council of Management those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of Trustees and auditors

As explained more fully in the Council of Management's Responsibilities set out on page 20, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditors under Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 and report in accordance with regulations made under those Acts.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the charitable company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the Trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Report of the Council of Management to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 July 2019 and of its incoming resources and application of resources, including its result, for the year then ended;
- have been properly prepared in accordance with the Financial Reporting Standards 102 (effective January 2015)
- have been prepared in accordance with the requirements of the Companies Act 2006, and Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Act 2011 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- the information given in the Report of the Council of Management is inconsistent in any material respect with the financial statements ; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.



Nicholas Hume

For and on behalf of Calcutt Matthews

Chartered Accountants and Registered Auditors

Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006

19 North Street

Ashford

Kent TN24 8LF

26 November 2019

ⁱ Royal College of Ophthalmologists. (2016). The Way Forward. Options to help meet demand for the current and future care of patients with eye disease. Glaucoma.

ⁱⁱ Kessels RP. (2003). Patients' memory for medical information. J R Soc Med 2003 May 96(5) 219-222.

The International Glaucoma Association Limited

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 July 2019

	Note	Restricted £	Unrestricted £	2019 Total £	2018 Total £
Income					
Donations, Legacies and Subscriptions	2	81,846	1,641,274	1,723,120	1,711,099
Glaucoma aids and equipment sales	4	9	10,644	10,653	13,786
Investment income	3	35,658	76,914	112,572	91,002
<i>Charitable activities</i>					
Other income	4	13,712	10,878	24,590	29,733
Total income		131,225	1,739,711	1,870,935	1,845,620
Expenditure on:					
<i>Raising funds</i>					
Finance and support		4,547	15,599	20,146	17,176
Costs of generating funds		12,596	94,850	107,446	110,523
Cost of glaucoma aids and equipment		-	7,055	7,055	8,153
		17,143	117,504	134,647	135,852
<i>Expenditure on charitable activities</i>					
Glaucoma research		156,614	164,108	320,722	261,313
Patient information and support		34,407	566,805	601,212	475,459
Professional information and support			73,355	73,355	129,717
Campaigning and advocacy		2,170	30,848	33,018	57,218
Total expenditure	5	210,334	952,620	1,162,954	1,059,561
Realised gains/(losses) on investment assets	11	(3,636)	(7,470)	(11,107)	14,745
Unrealised gains/(losses) on investment assets	11	46,375	95,272	141,647	168,719
Net (outgoing)/incoming resources before transfers	6	(36,370)	874,892	838,521	969,523
Gross transfer between funds		-	-	-	-
Net movement in funds		(36,370)	874,892	838,521	969,523
Reconciliation of funds					
Total funds brought forward		1,610,849	3,809,396	5,420,245	4,450,721
Total funds carried forward		1,574,479	4,684,288	6,258,766	5,420,245

All of the results above are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 17 to the financial statements.

The International Glaucoma Association Limited

Balance sheet

Charity No 274681
Scotland No SC041550
Company No. 1293286

As at 31 July 2019

	Note	2019 £	2018 £
Fixed assets			
Tangible fixed assets	10	8,621	2,001
Investments	11	<u>4,706,713</u>	<u>4,304,962</u>
Total fixed assets		4,715,334	4,306,963
Current assets			
Stock	12	8,120	3,241
Debtors	13	884,610	486,679
Cash at bank and in hand		<u>1,214,834</u>	<u>1,096,031</u>
		2,107,564	1,585,951
Liabilities			
Creditors: amounts due within one year	14 , 19	<u>414,271</u>	<u>417,669</u>
Net current assets		1,693,293	1,168,282
Total assets less current liabilities		6,408,627	5,475,245
Creditors: amounts falling due after more than one year	15	<u>149,861</u>	<u>55,000</u>
Net assets	16	6,258,766	5,420,245
Funds	17		
Restricted funds		1,574,474	1,610,849
Unrestricted funds			
Designated funds		1,992,906	1,692,906
General funds		<u>2,691,387</u>	<u>2,116,490</u>
Total funds		6,258,766	5,420,245


For the year ending 31/07/2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the Council of Management on 26 November 2019 and signed on its behalf by


David Sanders - Honorary Treasurer

The International Glaucoma Association Limited

Statement of cash flow

For the year ended July 2019

Cashflows from operating activities:	2019	2018
<i>Net cash provided by (used in) operating activities</i>	286,785	604,600
Cashflows from investing activities		
Dividends and interest from investments	112,572	91,002
Purchase of property, plant and equipment	(9,343)	-
Proceeds from sale of investments	710,611	515,832
Purchase of investments	(1,007,032)	(1,234,343)
<i>Net cash provided by (used in) investing activities</i>	(193,192)	(627,509)
<i>Change in cash and cash equivalents in the reporting period</i>	93,593	(22,909)
Cash and cash equivalents at the beginning of the reporting period	1,321,981	1,344,890
Cash and cash equivalents at the end of the reporting period	1,415,574	1,321,981
<i>Increase in cash balances</i>	93,593	(22,909)
Reconciliation of net movement in funds to net cash flow from operating activities		
<i>Net movements in funds for the reporting period (as per the statement of financial activities)</i>	838,521	969,523
Adjustments for:		
Depreciation	2,723	2,915
Dividends & interest from investments	(112,572)	(91,002)
Loss/(Profit) on sale of investments	(130,540)	(183,464)
(Increase)/Decrease in stocks	(4,879)	828
(Increase)/Decrease in debtors	(397,931)	(64,735)
Increase/(Decrease) in creditors	91,463	(29,465)
<i>Net cash provided by (used in) operating activities</i>	286,785	604,600
Analysis of cash and cash equivalents		
Cash in hand	1,214,834	1,096,034
Investments Capital account	200,740	225,947
	1,415,574	1,321,981

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

1. Accounting policies

- a) The financial statements have been prepared under the historical cost convention, as modified by the revaluation of fixed asset investments, and in accordance with applicable accounting standards and the Companies Act 2006. They follow the recommendations in the Statement of Recommended Practice, Accounting and Reporting by Charities. The accounting standards policies have been prepared under Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice) and SORP 2015. The Trustees review that the charitable activities are done as a public benefit entity.
The Trustees have reviewed the charity's financial position, and can confirm that the IGA will be able to continue operating as normal and to meet its obligations as they fall due; they have no plans to close the charity.
- b) Voluntary income received by way of subscriptions, donations and gifts is included in full in the statement of financial activities when receivable.
- c) Income from legacies is accounted for on a receivable basis, recognised when entitlement to the income has been established and it is probable that the IGA will receive the amounts ascertained. This treatment is within SORP 2015 and Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
Sales income represents sale of goods excluding VAT where appropriate.
Investment income is accounted for on a cash basis.
- d) Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.
- e) Unrestricted funds are donations and other incoming resources received or generated for general charitable purposes.
- f) Designated funds are unrestricted funds earmarked by the Board of Trustees for particular purposes. Within these funds is money awarded as grants, funding a range of research projects to develop more effective methods of glaucoma diagnosis and treatment.
- g) Costs of generating funds relates to the costs incurred in fundraising activities.
- h) Critical accounting judgements are used within these accounts as follows:
Residual legacy income debtors are valued at 85% of the expected value of the legacy when certain criteria are met and receipt is probable.
The support and governance costs are re-apportioned by staff time as explained in note (i). The staff costs attributed to each activity are reviewed twice a year.
- i) Resources expended are recognised in the period in which they are incurred. Resources expended include attributable VAT which cannot be recovered.
Resources expended are allocated to a particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function, is apportioned on the following basis which is an estimate based on staff time of the amount attributable to each activity.

Cost of generating funds	12%
Expenditure on charitable activities	76%
Research	3%
Governance costs	8%

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

1. Accounting policies (continued)

- j) Grants awarded are charged to the Statement of Financial Activities in the year in which they are awarded and are subject to receipt of progress reports.
- k) Governance costs are the costs associated with the governance of the charity, including constitutional and statutory requirements and costs associated with the strategic management of the charity's activities.
- l) Monetary assets and liabilities in foreign currencies are translated into sterling at the Bank of England exchange rate for that day.
- m) Investments held as fixed assets are revalued at market value at the balance sheet date. The Trustees consider that market value is a reasonably accurate representation of the fair value. The gain or loss for the period is taken to the statement of financial activities.
- n) The fixed assets are held at cost less depreciation and any impairment. Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

Fixtures, fittings and equipment	20%
Computers	33%

Items of equipment are capitalised where the purchase price exceeds £1,000. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

- o) Stocks are stated at the lower of cost and net realisable value. In general, cost is determined on a first in first out basis and includes transport and handling costs. Net realisable value is the price at which stocks can be sold in the normal course of business after allowing for the costs of realisation. Provision is made where necessary for obsolete, slow moving and defective stock. During the year the charity received donated items that have been stated at fair value.
- p) The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. Contributions payable are charged as an expense in the SOFA (Statement of financial activities) within staff costs then shared between the SOFA categories by staff time within these activities.
- q) Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the average rate of exchange for the year.

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

2. Voluntary income

	2019 Restricted £	2018 Restricted	2019 Unrestricted £	2018 Unrestricted	2019 Total £	2018 Total £
Donations and subscriptions	53,655	2,720	213,597	241,362	267,252	244,082
Corporate donors	-	-	20,450	15,200	20,450	15,200
Legacies	28,191	61,435	1,407,227	1,390,382	1,435,418	1,451,817
Total	81,846	64,155	1,641,274	1,646,944	1,723,120	1,711,099

3. Investment income

	2019 Restricted £	2018 Restricted	2019 Unrestricted £	2018 Unrestricted	2019 Total £	2018 Total £
Interest	55	-	3,773	1,665	3,828	1,665
Dividends from UK companies	28,390	29,203	58,322	37,799	86,712	67,002
Dividends from overseas companies	7,213	9,735	14,819	12,600	22,032	22,335
Total	35,658	38,938	76,914	151,510	112,572	91,002

4. Incoming resources from charitable activities

	2019 Restricted £	2018 Restricted	2019 Unrestricted £	2018 Unrestricted	2019 Total £	2018 Total £
Other Income						
Grants Received	13,712	20,246	10,400	4,638	24,112	24,884
Glaucoma aids and equipment sales	9	27	10,644	13,759	10,653	13,786
Miscellaneous	-	-	478	4,849	478	4,849
	13,721	20,273	21,522	23,246	35,243	43,519

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

5. Total Expenditure

	Cost of generating funds	Patient information and support	Professional information and support	Campaigning and advocacy	Glaucoma research	Finance and support	Governance	2019 Total	2018 Total
	£	£			£	£	£	£	£
Staff costs (Note 7)	52,151	277,647	31,520	9,878	14,152	85,783	33,258	504,387	482,634
Research grants (Note 8)	-	-	-	-	285,696	-	-	285,696	234,590
Regional outreach & helpline	-	32,465	478	-	-	78	-	33,021	27,891
Glaucoma aids & equipment	7,055	-	-	-	-	-	-	7,055	8,153
Awareness events, PR, social media & volunteering	-	23,153	10,642	15,079	-	-	-	48,874	38,326
AGM, annual lectures & trustee expenses	-	3,070	-	-	-	-	10,367	13,437	14,252
Fundraising	14,928	-	-	-	-	-	-	14,928	15,438
Premises and administration	-	49,102	6,317	416	-	154,478	-	210,312	193,654
Finance & professional	20,146	861	-	-	9,919	14,318	-	45,244	44,623
Expenditure	94,280	386,298	48,957	25,373	309,767	254,656	43,625	1,162,954	1,059,561
Finance and support reallocated	31,726	168,906	19,175	6,009	8,610	(254,657)	20,231		
Expense including Finance & Support	126,005	555,202	68,132	31,381	318,378	-	63,856	1,162,954	1,059,561
Governance reallocated	8,642	46,009	5,223	1,637	2,345	-	(63,857)		
Total Expenditure	134,647	601,212	73,355	33,018	320,722	-	-	1,162,954	1,059,561

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

6. Net (outgoing)/incoming resources

This is stated after charging/crediting:

	2019	2018
	£	£
Depreciation charge for the year - owned assets	2,723	2,915
Auditors' remuneration:		
audit	3,970	4,361
other services - accountancy	-	95
Trustees expenses	<u>5,656</u>	<u>5,469</u>

Trustees expenses represent the travel and subsistence costs of 12 (2018: 15) for 9 meetings.

During the accounting year unclaimed Trustees expenses totalled £167 (2018: £53).

Donations totalling £287 were received from Trustees, (2018: £1,167).

No Trustees received remuneration for their services during the financial year.

7. Staff costs and numbers

Staff costs were as follows:

	2019	2018
	£	£
Salaries and wages	445,989	422,293
Social security costs	39,249	42,113
Pension contributions	<u>19,148</u>	<u>18,228</u>
	<u>504,387</u>	<u>482,634</u>

The CEO was the sole staff member paid at the rate of £60,000 or more in the year as follows:

	2019	2018
	No.	No.
£60,000 - £70,000	1	1

Pension contributions in respect of the above full-time employee totalled £3,270 (2018: £3,270).

NI contributions in respect of the above employee totalled £7,853 (2018: £7,887)

The calculated unspent staff holiday entitlement at year end was £503, (2018: £707).

The charity contributes to a Royal London defined contribution pension scheme for employees.

The administration cost of operating this pension scheme was £300.

The Chief Executive Officer is the sole key management personnel having authority and responsibility for planning, directing and controlling the activities of the IGA.

Key management remuneration policy to set salary levels considers the following is factors:

The policy states cost of living, pay comparability, affordability and sustainability, and appropriateness. The policy states the ratio between the highest and lowest salary should be below 4.5:1 and the ratio between the highest and median (midpoint) salary is below 3.5:1

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

7. Staff costs and numbers (continued)

The average weekly number of employees (full-time equivalent) during the year was as follows:

	2019 No.	2018 No.
Cost of generating funds	1.28	1.49
Patient information and support	7.53	6.62
Professional information and support	1.10	1.45
Campaigning and awareness	0.33	0.50
Research	0.45	0.25
Governance	0.70	0.51
Finance and Support costs	2.04	1.89
	13.43	12.71

The actual number of staff including part time and full time in 2019 was 18 (2018 was 17)

8. Grants Awarded

	2019	2018
Mater Misericordiae University Hospital Dublin	30,000	-
Moorfields Eye Hospital NHS Foundation Trust	-	40,000
University College London's Institute of Ophthalmology - IGA Chair Fund	61,706	88,485
Cardiff University	30,000	(5,831)
The Royal College of Ophthalmologists	-	105,000
Fight for Sight	7,193	6,936
Ulster University	29,904	-
City University London	24,995	-
London School of Hygiene	99,960	-
	283,758	234,590

These grants were awarded in accordance with the IGA grants committee terms and conditions and grants policy, and were awarded to fund research into the diagnosis and treatment of glaucoma.

The negative figure represents an underspend on the grant awarded.

9. Taxation

The group is exempt from corporation tax and income tax as all its income is charitable and is applied for charitable purposes.

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

10. Tangible fixed assets

	Fixtures, fittings and equipment £	Computer equipment £	Total £
Cost			
At the start of the year	210,917	-	210,917
Additions in year	-	9,343	9,343
Disposals in year	-	-	-
At the end of the year	210,917	9,343	220,260
Depreciation			
At the start of the year	208,916	-	208,916
Charge for the year	400	2,323	2,723
Disposals in year	-	-	-
At the end of the year	209,316	2,323	211,639
Net book value			
At the end of the year	1,601	7,020	8,621
At the start of the year	2,001	-	2,001

11. Investments

	2019 £	2018 £
Market value at the start of the year	4,079,015	3,177,041
Additions at historic cost	1,007,032	1,234,343
Disposal proceeds	(710,611)	(515,832)
Realised gains/(losses)	(11,107)	14,745
Unrealised gains	141,647	168,718
Market value at the end of the year	4,505,976	4,079,015
Cash held as part of portfolio	200,740	225,947
Total	4,706,716	4,304,962
Historic cost at the end of the year	4,173,392	3,864,212

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

11. Investments (continued)

Investments comprise:

	2019	2018
		£
UK Equity	1,650,608	1,526,117
International Equity	1,915,858	1,705,073
Fixed Income	389,295	349,148
Alternatives	331,911	297,374
Property	218,321	201,303
Cash	200,740	225,947
	<u>4,706,733</u>	<u>4,304,962</u>

12. Stock

	2019	2018
	£	£
Goods for resale	<u>8,120</u>	<u>3,241</u>

13. Debtors

	2019	2018
	£	£
Trade debtors	31,963	18,100
Legacy debtors	810,899	435,771
Prepayments and accrued income	41,748	32,808
	<u>884,610</u>	<u>486,679</u>

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

14. Creditors: amounts due within one year

	2019 £	2018 £
Trade creditors	151,591	75,742
Obligations under grant agreement	140,876	275,194
Funds held as agent	87,969	33,300
Accruals	32,975	27,949
VAT Liability	859	5,484
	<u>414,271</u>	<u>417,669</u>

Funds held as agent represent those held for UKEGS and UKPGS, for which the IGA provides administration and infrastructure support as shown in note 19.

15. Creditors: amounts due after one year

	2019 £	2018 £
Obligations under grant agreements	149,861	55,000
	<u>149,861</u>	<u>55,000</u>

16. Analysis of net assets between funds

	Restricted funds £	Designated funds £	General funds £	Total funds £
Tangible fixed assets	-	-	8,621	8,621
Investments	1,492,978	300,000	2,913,735	4,706,713
Net current assets	-	-	1,693,293	1,693,293
Creditors: amounts falling due after more than one year	-	-	(149,861)	(149,861)
Net assets at the end of the year	<u>1,492,978</u>	<u>300,000</u>	<u>4,465,788</u>	<u>6,258,766</u>

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

17. Movements in funds

	At the start of the year £	Incoming resources £	Outgoing resources £	Other gains and losses £	Transfers £	At the end of the year £
Restricted funds:						
Chair Fund	1,471,663	50,582	(72,001)	42,733	-	1,492,978
North East Fund	79,998	-	(26,692)	-	-	53,306
Compliance Project Fund	9,119	-	(2,384)	-	-	6,735
Research Fund	44,412	51,371	(95,783)	-	-	-
Merseyside Fund	657	-	-	-	-	657
Folkestone Fund	5,000	-	(985)	-	-	4,015
Children and Young people's Support Fund	-	7,722	(939)	-	-	6,783
London Fund	-	20,000	(10,000)	-	-	10,000
Patient Support Fund	-	1,550	(1,550)	-	-	-
Total restricted funds	1,610,849	131,225	(210,334)	42,733	-	1,574,474
Unrestricted funds:						
<i>Designated funds:</i>						
Income Endowment	22,906	-	-	-	-	22,906
Equipment Replacement and Infrastructure Fund	370,000	-	-	-	-	370,000
Research investment fund	1,300,000	-	-	-	300,000	1,600,000
<i>Total designated funds</i>	1,692,906	-	-	-	300,000	1,992,906
General funds	2,116,490	1,739,711	(952,620)	87,807	(300,000)	2,691,387
Total unrestricted funds	3,809,396	1,739,711	(952,620)	87,807	-	4,684,293
Total funds	5,420,245	1,870,936	(1,162,954)	130,540	-	6,258,766

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

Movements in Funds

17. (continued)

Purposes of restricted funds

The Chair Fund is used to fund the post of IGA Professor of Ophthalmology for Glaucoma and Allied Studies at UCL.

The North East Fund was established following the receipt of a legacy and is restricted to supporting our work in the North East of England.

The Compliance Project Fund was granted by pharmaceutical companies to provide demonstration and educational eye drop materials.

The Research Fund represents donations received specifically to fund glaucoma research. The fund was drawn on throughout the year as detailed on Note 8.

The Merseyside Fund comprises legacy income restricted to the Merseyside area.

The Folkestone Fund comprises legacy income restricted to the Royal Victoria eye clinic in Folkestone.

The Children and Young People's Support Fund comprises appeal income and is being used to provide services for young people affected by glaucoma and their families and carers. It also helps us better understand their particular support needs so we can plan future services more effectively.

The London fund is restricted to the London area, we have used this fund mainly for awareness raising and support work with at-risk BAME communities.

The Patient support fund was received from a charitable Trust and was used to run a successful patient conference in Leicester.

The designated Equipment Replacement and Infrastructure Fund has been designated for equipment replacement, dilapidations and planned infrastructure development.

The designated Research Investment Fund was agreed by trustees in order to develop an income stream specifically to fund the charity's research priorities in the years ahead.

The International Glaucoma Association Limited

Notes to the financial statements

For the year ended 31 July 2019

18. Operating lease commitments

The charity had annual commitments at the year end under operating leases expiring as follows:

	Property	
	2019	2018
	£	£
Within one year	17,000	32,584
Within 1 -2 Years	68,000	32,584
Within 2 - 5 Years	68,000	82,168
Within 6-10 Years	-	34,000

The total future minimum lease payment is £153,000

Glaucoma UK Ltd, Glaucoma International Ltd, Glaucoma Europe Ltd, Glaucoma Association Ltd are dormant companies. Historically held by the IGA in order to protect the company identity and to give future flexibility in terms of the charity name.

19. Related Parties

Included in Note 14 are funds due to related parties held for the UK and Eire Glaucoma Society (UKEGS) and the UK Paediatric Glaucoma Society (UKPGS).

Financial Statement of UKEGS	2019	2018
	£	£
Income	259,097	92,668
Expenditure	(215,311)	(119,463)
Closing balance	43,785	(26,795)
Balance brought forward	22,364	49,159
Total funds held	66,149	22,364
Financial Statement of UKPGS	2019	2018
	£	£
Income	26,854	7,600
Expenditure	(15,968)	(2,355)
Closing balance	10,886	5,245
Balance brought forward	10,934	5,689
Total funds held	21,820	10,934